IL6 and breast cancer: Some studies indicate that immune cells and CAFs secrete IL-6 to activate JAK/STAT3 and PI3K/AKT signaling pathways in tumor cells, which results in the degradation of ERα through the ubiquitin protease pathway, leading to tamoxifen resistance in breast cancer (45).